美康生物
(300439)
| 流通市值：29.79亿 | | | 总市值：39.20亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 597,362,712.31 | 713,155,834.81 | 809,335,968.51 | 958,881,876.13 |
| 应收票据及应收账款 | 584,730,344.17 | 581,669,905.38 | 577,477,026.43 | 567,720,759.28 |
| 其中：应收票据 | - | - | 3,800,000 | - |
| 应收账款 | 584,730,344.17 | 581,669,905.38 | 573,677,026.43 | 567,720,759.28 |
| 应收款项融资 | 3,757,839.26 | - | 700,000 | 2,200,000 |
| 预付款项 | 43,869,139.08 | 32,905,872.74 | 43,220,656.4 | 44,410,140.14 |
| 其他应收款合计 | 19,241,477.55 | 19,676,411.7 | 28,874,205.08 | 36,324,036.15 |
| 存货 | 262,040,140.17 | 248,847,025.13 | 234,758,333.41 | 259,010,013.51 |
| 其他流动资产 | 31,693,233 | 27,319,059.54 | 26,602,849.3 | 24,618,716.88 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,798,075,174.43 | 1,811,787,373.19 | 1,791,170,239.13 | 1,899,165,542.09 |
| 非流动资产: | | | | |
| 长期股权投资 | 171,533,446.33 | 167,266,822.74 | 162,238,366.37 | 155,942,991.95 |
| 其他权益工具投资 | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 |
| 固定资产 | 995,393,574.65 | 990,198,260.24 | 962,788,212.03 | 981,583,751.96 |
| 在建工程 | 301,565,682.69 | 249,523,580.59 | 240,339,936.43 | 160,501,656.6 |
| 使用权资产 | 38,606,430.47 | 30,344,535.83 | 31,938,025.34 | 36,218,805.84 |
| 无形资产 | 122,258,116.33 | 123,685,133.95 | 125,473,102.75 | 127,847,100.31 |
| 长期待摊费用 | 28,198,745.04 | 31,070,351.71 | 28,792,764.04 | 34,342,037.15 |
| 递延所得税资产 | 43,674,924.35 | 42,570,972.97 | 36,386,059.69 | 35,530,610.39 |
| 其他非流动资产 | 58,892,770 | 59,338,260.98 | 56,073,416.98 | 53,053,441.7 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,765,123,689.86 | 1,698,997,919.01 | 1,649,029,883.63 | 1,590,020,395.9 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,563,198,864.29 | 3,510,785,292.2 | 3,440,200,122.76 | 3,489,185,937.99 |
| 流动负债: | | | | |
| 短期借款 | 30,022,083.33 | 30,022,083.33 | 30,022,083.33 | 50,053,733.33 |
| 应付票据及应付账款 | 313,209,221.66 | 340,429,128.94 | 319,810,952.03 | 333,462,927.37 |
| 其中：应付票据 | - | 20,000,000 | 35,000,000 | 15,000,000 |
| 应付账款 | 313,209,221.66 | 320,429,128.94 | 284,810,952.03 | 318,462,927.37 |
| 合同负债 | 50,313,950.19 | 51,848,224.97 | 50,378,404.6 | 88,269,591.08 |
| 应付职工薪酬 | 77,094,159.09 | 64,303,693.6 | 45,972,509.2 | 98,866,292.64 |
| 应交税费 | 28,749,888.43 | 17,855,763.97 | 32,640,205 | 27,099,725.41 |
| 其他应付款合计 | 68,024,229.65 | 71,925,481.54 | 74,084,895.65 | 71,773,367.09 |
| 一年内到期的非流动负债 | 11,522,232.34 | 11,302,653.43 | 17,459,388.17 | 19,521,788.09 |
| 其他流动负债 | 6,477,442.9 | 6,672,982.3 | 6,183,700.55 | 10,081,520.37 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 585,413,207.59 | 594,360,012.08 | 576,552,138.53 | 699,128,945.38 |
| 非流动负债: | | | | |
| 租赁负债 | 24,592,483.45 | 17,693,375.78 | 19,699,917.32 | 23,595,973.33 |
| 预计负债 | - | - | - | 1,448,971.32 |
| 递延收益 | 16,248,666.68 | 12,005,333.34 | 10,672,000 | 9,898,666.67 |
| 递延所得税负债 | 56,540,560.5 | 55,509,866.09 | 47,156,934.13 | 48,420,487.41 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 97,381,710.63 | 85,208,575.21 | 77,528,851.45 | 83,364,098.73 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 682,794,918.22 | 679,568,587.29 | 654,080,989.98 | 782,493,044.11 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 383,949,815 | 383,949,815 | 383,949,815 | 382,999,815 |
| 资本公积 | 1,118,487,183.12 | 1,117,049,138.66 | 1,115,611,094.2 | 1,109,299,549.74 |
| 减:库存股 | 5,907,940.75 | 5,907,940.75 | 5,907,940.75 | - |
| 其他综合收益 | -32,379,021.54 | -32,778,122.14 | -29,114,501.99 | -29,136,845.46 |
| 盈余公积 | 121,181,021.44 | 121,181,021.44 | 121,181,021.44 | 121,181,021.44 |
| 未分配利润 | 1,303,504,699.43 | 1,257,604,326.64 | 1,209,687,133.43 | 1,130,590,362.23 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,888,835,756.7 | 2,841,098,238.85 | 2,795,406,621.33 | 2,714,933,902.95 |
| 少数股东权益 | -8,431,810.63 | -9,881,533.94 | -9,287,488.55 | -8,241,009.07 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,880,403,946.07 | 2,831,216,704.91 | 2,786,119,132.78 | 2,706,692,893.88 |
| 负债和股东权益合计 | 3,563,198,864.29 | 3,510,785,292.2 | 3,440,200,122.76 | 3,489,185,937.99 |
| 公告日期 | 2024-10-26 | 2024-08-29 | 2024-04-24 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |